Dasatinib as Salvage Therapy for Steroid Refractory and Imatinib Resistant or Intolerant Sclerotic Chronic Graft-versus-Host Disease

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 2, 2012, Pages 318-323

  Sánchez Ortega, Isabel ^a,b   Servitje, Octavio ^c,d   Arnan, Montserrat ^a,d   Ortí, Guillermo ^a,d   Peralta, Teresa ^a,d   Manresa, Federico ^c,d   Duarte, Rafael F ^a,d  

^a HOSPITAL DURAN I REYNALS   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^d BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

Author keywords

Dasatinnib; Sclerotic chronic GVHD; Tirosine kinase inhibitors

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; DASATINIB; IMATINIB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; PSORALEN; STEROID;

ADD ON THERAPY; ADULT; ALOPECIA; ARTICLE; BRONCHIOLITIS OBLITERANS; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CYTOPENIA; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERANCE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DRY EYE; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; HYPOPIGMENTATION; IMMUNOSUPPRESSIVE TREATMENT; JOINT MOBILITY; LUNG DISEASE; LUNG FUNCTION TEST; MALE; MOUTH ULCER; PATIENT SELECTION; PHOTOPHOBIA; PRURITUS; PUVA; RANGE OF MOTION; SALVAGE THERAPY; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; BONE MARROW TRANSPLANTATION; CHRONIC DISEASE; DRUG RESISTANCE; FEMALE; GRAFT VS HOST DISEASE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SALVAGE THERAPY; SCLEROSIS; SKIN DISEASES; THIAZOLES; TRANSPLANTATION, HOMOLOGOUS;

EID: 84855612099     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.10.042     Document Type: Article

References (23)

1. Socie G., Stone J.V., Wingard J.R., et al. Long-term survival and late deaths after allogeneic bone marrow transplantation: Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med 1999, 341:14-21.
2. Wolff D., Schleuning M., von Harsdorf S., et al. Consensus conference on clinical practice in chronic GVHD: second-line treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2011, 17:1-17.
3. Skert C., Patriarca F., Sperotto A., et al. Sclerodermatous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: incidence, predictors and outcome. Haematologica 2006, 91:258-261.
4. Kantarjian H., Sawyers C., Hochhaus A., et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002, 346:645-652.
5. Roy L., Guilhot J., Krahnke T., et al. Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood 2006, 108:1478-1484.
6. Baroni S.S., Santillo M., Bevilacqua F., et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006, 354:2667-2676.
7. Svegliati S., Olivieri A., Campelli N., et al. Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood 2007, 110:237-241.
8. Distler J.H., Jungel A., Huber L.C., et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007, 56:311-322.
9. Distler J.H., Distler O. Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis. Rheumatology 2008, 47(Suppl 5):v10-v11.
10. Akhmetshina A., Venalis P., Dees C., et al. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum 2009, 60:219-224.
11. Magro L., Catteau B., Coiteux V., Bruno B., Jouet J.P., Yakoub-Agha I. Efficacy of imatinib mesylate in the treatment of refractory sclerodermatous chronic GVHD. Bone Marrow Transplant 2008, 42:757-760.
12. Moreno-Romero J.A., Fernandez-Aviles F., Carreras E., Rovira M., Martinez C., Mascaro J.M. Imatinib as a potential treatment for sclerodermatous chronic graft-vs-host disease. Arch Dermatol 2008, 144:1106-1109.
13. Magro L., Mohty M., Catteau B., et al. Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease. Blood 2009, 114:719-722.
14. Olivieri A., Locatelli F., Zecca M., et al. Imatinib for refractory chronic graft-versus-host disease with fibrotic features. Blood 2009, 114:709-718.
15. McFarland K.L., Wetzstein G.A. Chronic myeloid leukemia therapy: focus on second-generation tyrosine kinase inhibitors. Cancer Control 2009, 16:132-140.
16. Skhirtladze C., Distler O., Dees C., et al. Src kinases in systemic sclerosis: central roles in fibroblast activation and in skin fibrosis. Arthritis Rheum 2008, 58:1475-1484.
17. Akhmetshina A., Dees C., Pileckyte M., et al. Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J 2008, 22:2214-2222.
18. Tomblyn M., Chiller T., Einsele H., et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009, 15:1143-1238.
19. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005, 11:945-956.
20. Couriel D.R., Hosing C., Saliba R., et al. Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood 2006, 107:3074-3080.
21. Breccia M., Cannella L., Stefanizzi C., Carotti A., Santopietro M., Alimena G. Efficacy of dasatinib in a chronic myeloid leukemia patient with disease molecular relapse and chronic GVHD after haploidentical BMT: an immunomodulatory effect?. Bone Marrow Transplant 2009, 44:331-332.
22. Pulanic D., Cowen E.W., Baird K., Bishop M.R., Pavletic S.Z. Development of severe sclerotic chronic GVHD during treatment with dasatinib. Bone Marrow Transplant 2010, 45:1469-1470.
23. Kantarjian K., Shah N.P., Hochhaus A., et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myleoid leukemia. N Engl J Med 2010, 362:2260-2270.